Neoadjuvant combination immunotherapy improves outcomes for early stage non-small cell lung cancer

(University of Texas M. D. Anderson Cancer Center) The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news